Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01039025 · ClinicalTrials.gov registry record · Phase 2
TMC (Topotecan, Cyclophosphamide and Melphalan) for Multiple Myeloma
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT01039025: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT01039025 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 60 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01039025, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
To determine the efficacy of high-dose topotecan, cyclophosphamide and melphalan in patients with Multiple Myeloma.
Interventions
- DRUG Cyclophosphamide
- DRUG Melphalan
- DRUG Topotecan
- OTHER Peripheral Blood Stem Cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2002-02-18 |
| Est. Completion | 2006-05-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01039025
The ClinicalTrials.gov registry entry for NCT01039025 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Cyclophosphamide is the first listed.
NCT01039025 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01039025 about?
NCT01039025 is a clinical study titled "TMC (Topotecan, Cyclophosphamide and Melphalan) for Multiple Myeloma". To determine the efficacy of high-dose topotecan, cyclophosphamide and melphalan in patients with Multiple Myeloma.
What is the current status of trial NCT01039025?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2002-02-18. Estimated completion is 2006-05-19.
What interventions are being tested in trial NCT01039025?
The interventions under investigation include: Cyclophosphamide (DRUG), Melphalan (DRUG), Topotecan (DRUG), Peripheral Blood Stem Cells (OTHER).
Who is sponsoring clinical trial NCT01039025?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.